These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization. Hatooka M; Kawaoka T; Aikata H; Morio K; Kobayashi T; Hiramatsu A; Imamura M; Kawakami Y; Murakami E; Waki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Chayama K Anticancer Res; 2016 Jul; 36(7):3523-9. PubMed ID: 27354618 [TBL] [Abstract][Full Text] [Related]
6. Hepatic arterial infusion chemotherapy with cisplatin and sorafenib in hepatocellular carcinoma patients unresponsive to transarterial chemoembolization: a propensity score-based weighting. Kondo M; Morimoto M; Ishii T; Nozaki A; Fukuda H; Numata K; Kobayashi S; Ohkawa S; Hidaka H; Nakazawa T; Shibuya A; Okuse C; Suzuki M; Sakamaki K; Morita S; Maeda S; Tanaka K J Dig Dis; 2015 Mar; 16(3):143-51. PubMed ID: 25495751 [TBL] [Abstract][Full Text] [Related]
7. Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status. Kodama K; Kawaoka T; Aikata H; Uchikawa S; Inagaki Y; Hatooka M; Morio K; Nakahara T; Murakami E; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Masaki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Chayama K J Gastroenterol Hepatol; 2018 Oct; 33(10):1780-1786. PubMed ID: 29645345 [TBL] [Abstract][Full Text] [Related]
8. Comparison of clinical outcomes between sorafenib and hepatic artery infusion chemotherapy in advanced hepatocellular carcinoma: A STROBE-compliant article. Kang MK; Park JG; Lee HJ Medicine (Baltimore); 2018 Apr; 97(17):e0611. PubMed ID: 29703062 [TBL] [Abstract][Full Text] [Related]
9. Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis. Kodama K; Kawaoka T; Aikata H; Uchikawa S; Nishida Y; Inagaki Y; Hatooka M; Morio K; Nakahara T; Murakami E; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Masaki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Kimura T; Nagata Y; Chayama K Oncology; 2018; 94(4):215-222. PubMed ID: 29428943 [TBL] [Abstract][Full Text] [Related]
10. The efficacy of hepatic arterial infusion chemotherapy as an alternative to sorafenib in advanced hepatocellular carcinoma. Jeong SW; Jang JY; Lee JE; Lee SH; Kim SG; Cha SW; Kim YS; Cho YD; Kim HS; Kim BS; Kim KH; Kim YJ Asia Pac J Clin Oncol; 2012 Jun; 8(2):164-71. PubMed ID: 22524575 [TBL] [Abstract][Full Text] [Related]
11. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Ando E; Tanaka M; Yamashita F; Kuromatsu R; Yutani S; Fukumori K; Sumie S; Yano Y; Okuda K; Sata M Cancer; 2002 Aug; 95(3):588-95. PubMed ID: 12209752 [TBL] [Abstract][Full Text] [Related]
12. A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Song DS; Song MJ; Bae SH; Chung WJ; Jang JY; Kim YS; Lee SH; Park JY; Yim HJ; Cho SB; Park SY; Yang JM J Gastroenterol; 2015 Apr; 50(4):445-54. PubMed ID: 25027973 [TBL] [Abstract][Full Text] [Related]
13. Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability. Yoon EL; Yeon JE; Lee HJ; Suh SJ; Lee SJ; Kang SH; Kang K; Yoo YJ; Kim JH; Yim HJ; Byun KS J Clin Gastroenterol; 2014 Mar; 48(3):e22-9. PubMed ID: 24045282 [TBL] [Abstract][Full Text] [Related]
14. [Efficacy of Sorafenib versus Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization]. Shiozawa K; Watanabe M; Ikehara T; Matsukiyo Y; Kogame M; Okano N; Kikuchi Y; Igarashi Y; Sumino Y Gan To Kagaku Ryoho; 2015 Aug; 42(8):953-6. PubMed ID: 26321708 [TBL] [Abstract][Full Text] [Related]
15. Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective cohort study. Hayashi T; Yamashita T; Terashima T; Suda T; Okada H; Asahina Y; Hayashi T; Hara Y; Nio K; Sunagozaka H; Takatori H; Arai K; Sakai Y; Yamashita T; Mizukoshi E; Honda M; Kaneko S BMC Cancer; 2017 Dec; 17(1):870. PubMed ID: 29258450 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of sorafenib treatment and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a comparative study using the propensity score matching method. Fukubayashi K; Tanaka M; Izumi K; Watanabe T; Fujie S; Kawasaki T; Yoshimaru Y; Tateyama M; Setoyama H; Naoe H; Kikuchi K; Sasaki Y Cancer Med; 2015 Aug; 4(8):1214-23. PubMed ID: 26044168 [TBL] [Abstract][Full Text] [Related]
17. Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy. Estfan B; Byrne M; Kim R Am J Clin Oncol; 2013 Aug; 36(4):319-24. PubMed ID: 22547010 [TBL] [Abstract][Full Text] [Related]
18. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma. Finn RS; Poon RT; Yau T; Klümpen HJ; Chen LT; Kang YK; Kim TY; Gomez-Martin C; Rodriguez-Lope C; Kunz T; Paquet T; Brandt U; Sellami D; Bruix J J Hepatol; 2013 Dec; 59(6):1271-7. PubMed ID: 23928403 [TBL] [Abstract][Full Text] [Related]
19. Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature. Zavaglia C; Airoldi A; Mancuso A; Vangeli M; Viganò R; Cordone G; Gentiluomo M; Belli LS Eur J Gastroenterol Hepatol; 2013 Feb; 25(2):180-6. PubMed ID: 23044808 [TBL] [Abstract][Full Text] [Related]
20. Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial. Kondo M; Morimoto M; Kobayashi S; Ohkawa S; Hidaka H; Nakazawa T; Aikata H; Hatanaka T; Takizawa D; Matsunaga K; Okuse C; Suzuki M; Taguri M; Ishibashi T; Numata K; Maeda S; Tanaka K BMC Cancer; 2019 Oct; 19(1):954. PubMed ID: 31615466 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]